Author

Caroline Alvares

Cardiff UniversityORCID 0000-0003-4391-9802Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

Afsar Ali MianiD· 1 shared Andreas O. MielandiD· 1 shared Andreas Otto· 1 shared Carol Guy· 1 shared Christoph HieberiD· 1 shared Claudia ChirichesiD· 1 shared Dörte BecheriD· 1 shared Hannelore Held· 1 shared

Activity by Year

2018-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Afsar Ali MianORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintJun 20, 2025

Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes tyrosine kinase inhibitor resistance of acute myeloid leukemia cells

Melisa Halilovic, Mohamed Abdalla M. Abdelsalam, Andreas O. Mieland…·Oliver Holger Krämer

This study develops MA191, a PROTAC degrader of FLT3-ITD, which overcomes resistance in AML cells by rapidly degrading the mutant protein and shows efficacy in vivo.

2 citations

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 7, 2018

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated by an Oncogenic Transcription Factor in Acute Myeloid Leukemia

Nathalie Guillen, Maria Wieske, Andreas Otto…·Claudia Chiriches

This study uses subtractive interaction proteomics to identify signaling pathways activated by the t(6;9)-DEK/CAN oncogene in AML, revealing potential therapeutic targets.

DOI 10.1101/464958

humanproteomics

𝕏 PostBluesky